Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40–79 years

References

• Griffiths K, Eaton CL, Harper ME, Peeling B, Davies P. Steroid hormones and the pathogenesis of benign prostatic hyperplasia. Eur Urol 1991;(Suppl 1):(20)68–77.
   PubMedGoogle Scholar
• Carson C III, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003;61:2–7.
   PubMed Web of Science ®Google Scholar
• Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172:(5)1399–1403.
   Google Scholar
• Mirone V, Fusco F, Verza P, Schulman C, Debruyne F, Imbimbo C. Androgens and benign prostatic hyperplasia. Eur Urol 2006;(Suppl 5):410–417.
   PubMedGoogle Scholar
• Bartsch G, Rittmaster R, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000;37:367–380.
   PubMed Web of Science ®Google Scholar
• Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405–409.
   PubMed Web of Science ®Google Scholar
• Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995;26:40–49.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Ito K, Ichinose Y, Kurokawa K, Suzuki T, Imai K, Yamanaka H, Honma S. Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration. Scand J Urol Nephrol 1995;29:65–68.
   PubMed Web of Science ®Google Scholar
• Meikle AW, Stephenson RA, Lewis CM, Middleton RG. Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins. J Clin Endocrinol Metab 1997;82:571–575.
   PubMed Web of Science ®Google Scholar
• Platz EA, Kawachi I, Rimm EB, Longcope C, Stampfer MJ, Willett WC, Giovannucci E. Plasma steroid hormones, surgery for benign prostatic hyperplasia, and severe lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1999;2:285–289.
   PubMedGoogle Scholar
• Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, Szalay A, Djavan B, Schmidbauer CP, Söregi S, Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000;55:397–402.
   Google Scholar
• Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935–944.
   PubMed Web of Science ®Google Scholar
• Joseph MA, Wei JT, Harlow SD, Cooney KA, Dunn RL, Jaffe CA, Montie JE, Schottenfeld D. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate 2002;53:322–329.
   PubMed Web of Science ®Google Scholar
• Zhuang TN, Ly LP, Cumming RG, Handelsman DJ. Growth and development during early manhood as determinants of prostate size in later life. J Clin Endocrinol Metab 2005;90:6055–6063.
   PubMedGoogle Scholar
• Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 2004;61:124–131.
   PubMed Web of Science ®Google Scholar
• Liu CC, Huang SP, Li WM, Wang CJ, Chou YH, Li CC, Huang CH, Wu WJ. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology 2007;70:677–680.
   PubMed Web of Science ®Google Scholar
• Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2008;168:1416–1424.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. J Urol 2010;184:1040–1044.
   PubMed Web of Science ®Google Scholar
• Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, Barrett-Connor E. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int 2010;105:1554–1559.
   PubMed Web of Science ®Google Scholar
• Wilson JD, Roehrborn C. Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab 1999;84:4324–4231.
   PubMed Web of Science ®Google Scholar
• Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Vaughan ED, Markisz JA, Ramirez de Arellano E, Kazam E. Prostate visualization studies in males homozygous and heterozygous for 5α-reductase deficiency. J Clin Endocrinol Metab 1992;75:1022–1026.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505–508.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434–441.
   PubMed Web of Science ®Google Scholar
• Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–471.
   PubMed Web of Science ®Google Scholar
• Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004;6:S3–S10.
   Google Scholar
• Wenderoth UK, George FW, Wilson JD. The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate. Endocrinology 1983;113:569–573.
   PubMedGoogle Scholar
• Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl 2002;25:119–125.
   PubMedGoogle Scholar
• Moghissi E, Ablan F, Horton R. Origin of plasma androstanediol glucuronide in men. J Clin Endocrinol Metab 1984;59:417–421.
   PubMedGoogle Scholar
• Horton R. Benign prostatic hyperplasia: new insights. J Clin Endocrinol Metab 1992;74:504A–504C.
   Google Scholar
• Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 1993;150:1736–1739.
   PubMedGoogle Scholar
• Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, Hankin J, Teh CZ, Dreon DM, Paffenbarger RS Jr. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995;4:735–741.
   PubMed Web of Science ®Google Scholar
• Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB; BACH Survey Investigators. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int 2007;100: 321–326.
   PubMed Web of Science ®Google Scholar